Maria Laura Freeman, OD
Optometrist · San Diego, CANPI 1528490430
Payments from drug & device makers
Across 98 payments — averaging $58.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Bausch & Lomb Americas Inc.$820
- AbbVie$399
- Mallinckrodt Hospital Products Inc.$377
- Harrow Eye, LLC$359
- Sun Pharmaceutical Industries Inc.$343
- plus $2K from 14 others
What the payments were for
- Travel & lodging$4408%
- Food & beverage$5,24992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 11 | $1,589 |
| Bausch & Lomb Americas Inc. | 21 | $820 |
| AbbVie(2 entities) | 6 | $399 |
| Mallinckrodt Hospital Products Inc. | 6 | $377 |
| Harrow Eye, LLC | 6 | $359 |
| Sun Pharmaceutical Industries Inc. | 7 | $343 |
| Oyster Point Pharma, Inc. | 10 | $328 |
| Alcon | 2 | $280 |
| Tarsus Pharmaceuticals, Inc. | 6 | $275 |
| Shire North American Group Inc | 1 | $124 |
| Genentech, Inc. | 1 | $119 |
| Amgen(2 entities) | 5 | $116 |
| Visioneering Technologies, Inc. | 1 | $114 |
| Coopervision Inc. | 1 | $111 |
| Novartis | 6 | $108 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $99 |
| Ocular Therapeutix, Inc. | 1 | $43 |
| Dompe US, Inc. | 1 | $34 |
| Sight Sciences, Inc. | 2 | $29 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,689 in reported general payments places this provider in the 90th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 94 | $171,778 |
| RestasisCyclosporine | 123 | $128,285 |
| MieboPerfluorohexyloctane/Pf | 108 | $92,794 |
| CequaCyclosporine | 65 | $79,317 |
| Cyclosporine | 106 | $68,741 |
| XiidraLifitegrast | 40 | $59,159 |
| TyrvayaVarenicline Tartrate | 36 | $37,205 |
| VevyeCyclosporine | 20 | $14,314 |
| Loteprednol Etabonate | 34 | $4,253 |
| AzasiteAzithromycin | 13 | $3,107 |
| Ofloxacin | 24 | $213 |
| ErythromycinErythromycin Base | 20 | $189 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 17 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $275 | $171,77894 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $820 | $151,953148 claims |
| AbbVieRestasis | $399 | $128,285123 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $343 | $79,31765 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $328 | $37,20536 claims |
| Harrow Eye, LLCVevye | $359 | $14,31420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,778 optometrist providers in California.
Other optometrist in San Diego
- Keith WanSan Diego$887K
- David GeffenSan Diego$384K
- Jason TuSan Diego$351K
- Dorothy WangSan Diego$312K
- Alicia LauSan Diego$300K
- Melody TavakoliSan Diego$267K
- Brian ChouSan Diego$243K
- Eric WhiteSan Diego$211K
- Elliott ShapiroSan Diego$135K
- Brittany McMurrenSan Diego$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.